EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Novel radiohybrid PET-Tracers for SST2-targeted imaging of neuroendocrine tumors

Lennard Wendlinger iD, Mara Parzinger, Alexandra Litvinenko iD, David Viertl iD, Philipp Spatz iD, Alexander Wurzer iD, Hans-Jürgen Wester iD, Margret Schottelius iD

European Journal of Nuclear Medicine and Molecular Imaging · 2026

DOI: 10.1007/s00259-025-07638-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Lennard Wendlinger und 7 weiteren Autor:innen. Beteiligte Einrichtung: Translational Radiopharmaceutical Sciences, Centre Hospitalier Universitaire Vaudois, Lausanne, 1005, Switzerland. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Receptors, Somatostatin, Positron-Emission Tomography, Radiopharmaceuticals. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Lausanne.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

68 Ga- and 177 Lu-labeled theranostic companion tracers have become a mainstay in the clinical management of SST 2 overexpressing neuroendocrine tumors. Despite the excellent radionuclide characteristics of [ 18 F]fluorine for PET imaging, 18 F-labeled SST 2 -targeted tracers remain underrepresented. Novel radiohybrid SST 2 -tracers with DOTA as a bridging unit were designed, allowing radiolabeling with either 18 F or 68 Ga.

Methods

Seven DOTA-TATE derivatives (rhTATE1/2: N -SiFA lin - N , N -Me 2 -Gly- d -Dap/Lys( trans -DOTA-TATE)-OH and (rhTATE2.1-2.5: H-AA1-AA2-AA3- d -Dap( N -SiFA lin - N , N -Me 2 -Gly)- d -Lys( trans -DOTA-TATE)-OH) with different linkers and hydrophilic modifiers (AA1-AA3) were synthesized and compared to [ 18 F]SiTATE. Competitive binding studies (IC 50 ) were performed using hSST 2 -CHO cells and [ 125 I]TOC. Internalization was investigated using AR42J cells. Biodistribution and PET/CT studies were performed using AR42J xenograft bearing CD1 nu/nu mice. SST 2 specificity was confirmed in a blocking study (+/- co-injection of octreotide).

Results

While the first-generation compounds showed good affinity (IC 50 : [ nat Ga]rhTATE1: 5.6 ± 1.4 n m , [ nat Ga]rhTATE2: 5.7 ± 0.2 n m ) but high lipophilicity (LogD pH=7.4 = -1.03 and − 1.19), the inclusion of hydrophilic modifiers ([ nat Ga]rhTATE2.1-[ nat Ga]rhTATE2.5) improved affinity (IC 50 : 2.6 to 3.7 n m ) and hydrophilicity (LogD pH=7.4 = -2.30 to -2.12). The compounds demonstrated efficient internalization (357% to 841% compared to [ 125 I]TOC), and variable human serum albumin affinity (84.8% to 98.8%). [ 18 F][ nat Ga]rhTATE2.2 showed the highest tumor accumulation (27.9 ± 4.8%iD/g), while [ 18 F][ nat Ga]rhTATE2.5 showed lower tumor uptake (18.6 ± 6.2%iD/g), but substantially lower background accumulation, providing improved tumor-to-organ ratios.

Conclusion

This study demonstrates a SST 2 -targeted radiohybrid concept using bifunctionalized DOTA as a bridging unit. N -terminal modifications with hydrophilic tripeptides improved the pharmacokinetic properties. [ 18 F][ nat Ga]rhTATE2.5 ( d -Glu- d -Glu- d -Glu) compares particularly well to [ 18 F]SiTATE regarding background clearance and tumor accumulation, with the additional advantage of radiohybrid radiolabeling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsReceptors, SomatostatinPositron-Emission TomographyRadiopharmaceuticalsAnimalsHumansMiceCell Line, TumorGallium RadioisotopesTissue DistributionHeterocyclic Compounds, 1-RingRadioactive Tracers

Stichwörter der Autor:innen

DOTA-TATEFluorine-18Gallium-68PET imagingRadiohybrid

Substanzen

Receptors, SomatostatinGallium RadioisotopesHeterocyclic Compounds, 1-RingRadioactive TracersRadiopharmaceuticalssomatostatin receptor 2

Autor:innen und Institutionen

  • Translational Radiopharmaceutical Sciences, Centre Hospitalier Universitaire Vaudois, Lausanne, 1005, Switzerland.
  • AGORA, Pôle de recherche sur le cancer, Lausanne, 1005, Switzerland.
  • Pharmaceutical Radiochemistry, Technical University of Munich, Garching, 85748, Germany.
  • Scintomics Molecular, Applied Theranostics Technologies GmbH, 82256, Fürstenfeldbruck, Germany.
  • Translational Radiopharmaceutical Sciences, Centre Hospitalier Universitaire Vaudois, Lausanne, 1005, Switzerland. margret.schottelius@chuv.ch.
  • AGORA, Pôle de recherche sur le cancer, Lausanne, 1005, Switzerland. margret.schottelius@chuv.ch.

ORCID-Profile: Lennard Wendlinger, Alexandra Litvinenko, David Viertl, Philipp Spatz, Alexander Wurzer, Hans-Jürgen Wester, Margret Schottelius

Förderung

  • University of Lausanne

Zitieren

APA

Wendlinger, L., Parzinger, M., Litvinenko, A., Viertl, D., Spatz, P., Wurzer, A., Wester, H. J., & Schottelius, M. (2026). Novel radiohybrid PET-Tracers for SST2-targeted imaging of neuroendocrine tumors. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07638-9

Vancouver

Wendlinger L, Parzinger M, Litvinenko A, Viertl D, Spatz P, Wurzer A, et al. Novel radiohybrid PET-Tracers for SST2-targeted imaging of neuroendocrine tumors. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-025-07638-9

BibTeX
@article{Wendlinger2026,
  author = {Wendlinger, Lennard and Parzinger, Mara and Litvinenko, Alexandra and Viertl, David and Spatz, Philipp and Wurzer, Alexander and Wester, Hans-Jürgen and Schottelius, Margret},
  title = {Novel radiohybrid PET-Tracers for SST2-targeted imaging of neuroendocrine tumors},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  doi = {10.1007/s00259-025-07638-9}
}
Kostenlos starten →